EN DE
Watch GUJARAT TERCE LABORATORIES LTD. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

GUJARAT TERCE LABORATORIES LTD. (GUJTERC) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of GUJARAT TERCE LABORATORIES LTD. stock ₹46.41, price ₹41.13, upside +12.8%, quality 59 out of 100. Rating: undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE499G01013

GT GUJARAT TERCE LABORATORIES LTD. logo Thin data Nov 22, 2026

GUJARAT TERCE LABORATORIES LTD.

GUJTERC · BSE

Solid company, but only slightly cheap (11% below fair value) and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Fair value ₹46.41 · Undervalued 
Low debt 
Generates free cash flow 
Ranks above peers (9/13) 
27% return on equity. 
Quality 59/100 
Mixed Growth (revenue 5y +13.5 %/yr in INR) 
Thin margins · 4.4% net margin (TTM) 
Moderate moat 51/100 · thin data
Falling price (downtrend) 
Thin data 
Watch GUJARAT TERCE LABORATORIES LTD. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹89.21 ₹8.19 Fair Value ₹46.41 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.

How to read this chart

60‑month range ₹8.19 – ₹89.21 · fair‑value band ₹31.15 – ₹65.90 · the ₹41.13 price screens below the ₹46.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 22, 2026.

Follow GUJARAT TERCE LABORATORIES in your weekly email

Every Wednesday you see whether GUJARAT TERCE LABORATORIES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally.

Show moreShow less

The company's products include branded generic pharmaceutical covering various therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrology, gynecology, pain therapy, and ayurvedic.

It provides its products in various forms, including tablets, capsules, oral liquids, ointments, and injections under the Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, and Aziter brands. Gujarat Terce Laboratories Limited was incorporated in 1985 and is based in Ahmedabad, India.

Stock analysis

GUJARAT TERCE LABORATORIES LTD. (GUJTERC) currently trades at ₹41.13, while our model-based Fair Value estimate is ₹46.41, implying the stock looks roughly 11% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹58.72 per share, and 14 of the 23 models we run sit above the ₹41.13 price.

Bear case: the Asset-Based group reads lowest at ₹8.37, and 9 of the 23 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹31.15 (bear) to ₹65.90 (bull), the price of ₹41.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

GUJARAT TERCE LABORATORIES LTD. reported revenue of ₹475M in FY2026 versus ₹401M in FY2022, a compound +4.3%/yr. Reported net income was ₹22.0M in FY2026, compounding +26.0%/yr from FY2022.

Key figures

Market cap ₹320M (≈ $3.5M) Micro · P/E ratio 15.5 · P/S ratio 0.71 · EPS (TTM) ₹2.65 · Net margin 4.4% · Return on equity 27.2% · Return on assets (EBIT) 5.9% (5-year average) · Operating margin 5.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at 13%, GUJTERC screens cheaper than that median.

Fair Value models

Bear ₹31.15 Fair Value ₹46.41 Bull ₹65.90
Price ₹41.13 · Upside +12.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹1.71 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹23.71 ₹30.87 ₹39.66 82
Growth DCF ₹23.90 ₹30.26 ₹37.66 80
Owner Earnings ₹19.33 ₹24.93 ₹31.80 78
All 23 models by family
DCF Models
FCF DCF ₹23.71 ₹30.87 ₹39.66 82
Owner Earnings ₹19.33 ₹24.93 ₹31.80 78
5Y Revenue Exit ₹33.05 ₹50.77 ₹73.03 72
5Y EBITDA Exit ₹37.49 ₹58.83 ₹83.13 75
5Y P/E Exit ₹35.55 ₹55.31 ₹75.42 71
10Y Revenue Exit ₹27.79 ₹41.56 ₹59.30 67
10Y EBITDA Exit ₹31.15 ₹46.41 ₹65.90 68
10Y P/E Exit ₹30.07 ₹44.29 ₹60.87 64
Earnings-Based
Graham-Dodd ₹19.22 ₹51.01 ₹66.67 65
PEG = 1.0 ₹9.85 ₹14.07 ₹18.29 57
EPV ₹32.50 ₹36.17 ₹39.18 74
Multiples
P/E Multiple ₹46.63 ₹62.17 ₹77.71 63
P/S Multiple ₹36.03 ₹48.04 ₹60.05 58
P/B Multiple ₹19.08 ₹25.45 ₹31.81 55
EV/EBIT ₹54.21 ₹72.35 ₹90.49 66
EV/EBITDA ₹50.30 ₹67.14 ₹83.98 67
EV/Revenue ₹38.63 ₹55.27 ₹71.92 53
Asset-Based
NCAV (Graham) ₹6.24 ₹8.37 ₹12.49 54
Growth DCF
Growth DCF ₹23.90 ₹30.26 ₹37.66 80
Rev-Margin DCF ₹33.05 ₹50.79 ₹70.25 73
Economic Profit
Residual Income ₹14.44 ₹17.87 ₹25.30 70
ROIC Compounder ₹33.49 ₹38.41 ₹43.16 72
Growth Earnings
Growth-Adj P/E ₹36.45 ₹52.07 ₹67.70 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 73
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 43
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 41
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.6%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−10% → 7%

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +8.1% a year for the price.

Watch GUJTERC, get fair value alerts →

Compare GUJARAT TERCE LABORATORIES LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 611 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside +12.8% · Above median
Profitability
Return on equity (12 months) 27.2% · Top 25%
Return on assets 9.0% · Top 25%
Net margin (12 months) 4.4% · Below median
Operating margin (12 months) 5.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) −1.2% · Below median
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 15.5× · Cheaper than median
P/B 3.29× · Priciest 25%
P/S (12 months) 0.71× · Cheapest 25%
Price / free cash flow (fiscal year) 19.0× · Cheaper than median
EV/EBITDA 9.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 22
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)100 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.11 $113.53 +44% vs GUJTERC
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.00 ¥51.70 +10% vs GUJTERC
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,884.90 ₹1,982.92 +5% vs GUJTERC
Haleon plc HLN $9.07 $8.47 −7% vs GUJTERC
Merck KGaA MRK €146.45 €108.83 −26% vs GUJTERC
Galderma Group GALD CHF 182.85 CHF 112.84 −38% vs GUJTERC
Teva Pharmaceutical Industries Limited TEVA $39.23 $20.74 −47% vs GUJTERC
Takeda Pharmaceutical Company TAK $21.77 $11.26 −48% vs GUJTERC
Sandoz Group SDZ CHF 80.50 CHF 40.87 −49% vs GUJTERC
Divi's Laboratories Limited DIVISLAB ₹11,180.50 ₹1,566.89 −86% vs GUJTERC

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GUJARAT TERCE LABORATORIES LTD.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GUJARAT TERCE LABORATORIES LTD. Fair Value". https://www.fairvalue-calculator.com/stock/GUJTERC

Frequently asked questions

Is GUJARAT TERCE LABORATORIES LTD. (GUJTERC) overvalued or undervalued?
As of Nov 22, 2026, our model estimates a fair value of ₹46.41 versus a price of ₹41.13, about +13% upside (undervalued).
What is the fair value of GUJTERC?
Our model-based fair value for GUJARAT TERCE LABORATORIES LTD. is ₹46.41 (as of Nov 22, 2026), built from audited fundamentals. The current price: ₹41.13.
What is the quality score of GUJTERC?
GUJARAT TERCE LABORATORIES LTD. has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
We do not set a price target; the yardstick is the fair value of ₹46.41 (as of Nov 22, 2026) from 23 valuation models. Cautious scenario ₹31.15, optimistic scenario ₹65.90. It is a calculation from audited fundamentals, not an analyst target.
What is the GUJARAT TERCE LABORATORIES LTD. stock forecast for 2026?
Our models put fair value at ₹46.41, about +13% upside versus a price of ₹41.13 (undervalued). Cautious scenario ₹31.15, optimistic scenario ₹65.90. The calculation is refreshed regularly with new filings.
What is the revenue of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
GUJARAT TERCE LABORATORIES LTD. reported trailing-twelve-month revenue of about ₹455M (latest available figure, as of Nov 22, 2026).
What growth is priced into GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
For today's price to be fair in a discounted-cash-flow model, GUJARAT TERCE LABORATORIES LTD. would have to grow free cash flow by 12.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 13.5 % per year. As of Nov 22, 2026.
What discount rate (WACC) does the fair value of GUJTERC use?
Our models discount GUJARAT TERCE LABORATORIES LTD. at 11.8 %: a base by market capitalisation (nano), damped by beta 0.82, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GUJARAT TERCE LABORATORIES LTD. that is +12.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has GUJARAT TERCE LABORATORIES LTD. (GUJTERC) delivered so far?
Over the past 5 years revenue at GUJARAT TERCE LABORATORIES LTD. grew 13.5 % a year. The price currently implies free-cash-flow growth of +12.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GUJARAT TERCE LABORATORIES LTD. (GUJTERC) growing?
The median revenue growth in the sector is +3.7 % a year. That is the yardstick for the growth priced into GUJARAT TERCE LABORATORIES LTD. (+12.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The free-cash-flow yield on the price is 5.26 %: that much free cash flow GUJARAT TERCE LABORATORIES LTD. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GUJARAT TERCE LABORATORIES LTD. it is ₹46.41 per share (as of Nov 22, 2026), against a price of ₹41.13. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is GUJARAT TERCE LABORATORIES LTD. stock overvalued or undervalued in 2026?
As of Nov 22, 2026, GUJTERC trades below its calculated fair value: price ₹41.13, fair value ₹46.41, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GUJTERC?
No. The price is what the market pays today (₹41.13); the fair value is what the company's own numbers justify (₹46.41). For GUJARAT TERCE LABORATORIES LTD. the two are ₹5.28 per share apart. That gap is exactly why we show both numbers side by side.
How much is GUJARAT TERCE LABORATORIES LTD. worth?
The market values GUJARAT TERCE LABORATORIES LTD. at about ₹320M (market capitalisation, as of Nov 22, 2026). Per share that is ₹41.13; our models calculate a fair value of ₹46.41 per share.
What do the bullish and bearish scenarios say about GUJTERC?
Our models span a range for GUJARAT TERCE LABORATORIES LTD.: cautious scenario ₹31.15, base ₹46.41, optimistic ₹65.90 per share (as of Nov 22, 2026, price ₹41.13). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GUJTERC?
GUJARAT TERCE LABORATORIES LTD. trades at a price-to-earnings ratio of 15.5 (as of Nov 22, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹46.41 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2019 to 2026), reported earnings: 17.0. Other multiples: P/B 3.3, P/S 0.7, EV/EBITDA 9.6.
How solid is the balance sheet of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
Balance-sheet figures for GUJARAT TERCE LABORATORIES LTD. (as of Nov 22, 2026): return on equity 27.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is GUJTERC from its 52-week high?
GUJARAT TERCE LABORATORIES LTD. trades at ₹41.13, about 16% below its 52-week high of ₹48.95 and 33% above the low of ₹30.90 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ₹46.41 is for.
Which stocks are comparable to GUJARAT TERCE LABORATORIES LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GUJARAT TERCE LABORATORIES LTD. stock attractive at the current price?
The data as of Nov 22, 2026: price ₹41.13, calculated fair value ₹46.41 (+13%), Quality Score 59/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GUJTERC calculated?
We run GUJARAT TERCE LABORATORIES LTD. through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹46.41 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. GUJARAT TERCE LABORATORIES LTD. currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The closing price on Nov 20, 2026 was ₹41.13. Our model-based fair value is ₹46.41, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GUJARAT TERCE LABORATORIES LTD. right now?
A fairly wide model range (₹31.15 to ₹65.90) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of GUJARAT TERCE LABORATORIES LTD.

How large is the market capitalisation of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The market capitalisation of GUJARAT TERCE LABORATORIES LTD. is ₹320M (≈ $3.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The price-to-sales ratio of GUJARAT TERCE LABORATORIES LTD. is 0.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
Earnings per share at GUJARAT TERCE LABORATORIES LTD. are ₹2.65 (price ÷ EPS = P/E 15.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The net margin of GUJARAT TERCE LABORATORIES LTD. is 4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The return on equity (ROE) of GUJARAT TERCE LABORATORIES LTD. is 27.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
On an EBIT basis the return on assets of GUJARAT TERCE LABORATORIES LTD. is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
The operating margin of GUJARAT TERCE LABORATORIES LTD. is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
Revenue at GUJARAT TERCE LABORATORIES LTD. is down 1.2% in the last quarter versus the same quarter a year earlier (3y avg +0.5%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at GUJARAT TERCE LABORATORIES LTD. (GUJTERC)?
Earnings per share at GUJARAT TERCE LABORATORIES LTD. are down 6.1% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much net debt does GUJARAT TERCE LABORATORIES LTD. (GUJTERC) carry?
The net debt of GUJARAT TERCE LABORATORIES LTD. is ₹1.6M (fiscal year 2025, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GUJARAT TERCE LABORATORIES LTD. in the live analysis

One click puts GUJARAT TERCE LABORATORIES LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.